ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gyneco

[News]

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

More... (https://www.news-medical.net/news/20240916/ESMO-2024-Promising-results-in-immunotherapy-and-antibody-drug-conjugates-for-gynecological-cancers.aspx)